Skip to main content
Psych Regionals Main banner
Back

Evolving Perspectives on Depression: Chronic vs. Episodic Treatment in MDD and the Role of the GABA System

Thursday, July 27, 2023
11:45 AM – 12:45 PM USA

    Presenter(s)

  • Rakesh Jain, MD

    Clinical Professor
    Texas Tech - Permian Basin
    Texas Tech University School of Medicine - Permian Basin, Midland, Texas
    Austin, Texas

  • Greg Mattingly, MD

    Associate Clinical Professor, Washington University in St. Louis; President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders
    St.Charles Psychiatric Associates
    Washington University School of Medicine
    St.Charles, Missouri

  • Ahmed Baig, MD

    Chief Medical Officer
    Midwest Research Group
    St. Louis, Missouri

  • CM

    Cheryl Meier

    Patient Advocate
    Midwest Research Group
    O Fallon, Missouri

Disclosure(s):
Greg Mattingly, MD: No relevant disclosure to display
Ahmed Baig, MD: No financial relationships to disclose
Cheryl Meier: No financial relationships to disclose
Major depressive disorder (MDD) is a highly impairing disorder that can affect many areas of one’s life. Our experts will differentiate the clinical needs associated with episodic versus chronic depression, describe the pathophysiologic role of GABA in neurotransmitter dysfunction among individuals with MDD or postpartum depression (PPD), and share the optimal treatment strategies given the mechanisms of action and latest clinical data associated with antidepressant medications for MDD and PPD. Join our faculty in a live Q&A session immediately following their presentation where they will answer the most popular questions. This activity has been supported through an independent educational grant from Sage Therapeutics, Inc. and Biogen Inc.

Learning Objectives:

  • Differentiate among the clinical needs associated with episodic versus chronic depression
  • Summarize the pathophysiologic role of GABA in neurotransmitter dysfunction in patients with MDD or PPD
  • Implement optimal treatment strategies by considering the mechanisms of action and most recent clinical data associated with antidepressant medications for MDD or PPD
  • Practice collaborative care and shared decision making when caring for patients with MDD or PPD